Sideris Nikolaos, Vakirlis Efstratios, Tsentemeidou Aikaterini, Kourouklidou Alexandra, Ioannides Demetrios, Sotiriou Elena
Dermatology Department, School of Medicine, Aristotle University, Thessaloniki, Greece.
Mediterr J Rheumatol. 2020 Jun 11;31(Suppl 1):137-144. doi: 10.31138/mjr.31.1.137. eCollection 2020 Jun.
Molecular targeting therapies represent a new exciting era in dermatology. A promising novel drug class, subject of intense research, is Janus kinase (JAK) inhibitors. Multiple cytokine receptors signal through the Janus kinase and signal transducer and activator of transcription (STAT) pathway. The pathway plays a central role in innate and adaptive immunity, and haematopoiesis. The understanding of the contribution of JAKs to the immunologic processes of inflammatory diseases led to the development of JAK inhibitors, initially for rheumatologic and hematologic diseases. Soon, their efficacy in some dermatologic conditions was also demonstrated, and today their role as therapeutic agents is thoroughly researched, mainly in atopic dermatitis, psoriasis, vitiligo, and alopecia areata. JAK inhibitors can be administered orally or used topically. As they are relatively new treatment modalities in dermatology, many questions concerning their efficacy and safety remain unanswered. Data from ongoing trials are eagerly awaited. Here, we summarize under development JAK inhibitors for dermatologic diseases.
分子靶向疗法代表了皮肤病学领域一个令人兴奋的新时代。一类前景广阔且正在深入研究的新型药物是 Janus 激酶（JAK）抑制剂。多种细胞因子受体通过 Janus 激酶以及信号转导和转录激活因子（STAT）途径进行信号传导。该途径在先天性和适应性免疫以及造血过程中起着核心作用。对 JAK 在炎症性疾病免疫过程中作用的认识促使了 JAK 抑制剂的研发，最初用于治疗风湿性和血液学疾病。很快，它们在某些皮肤病中的疗效也得到了证实，如今其作为治疗药物的作用正在得到深入研究，主要用于特应性皮炎、银屑病、白癜风和斑秃。JAK 抑制剂可以口服或局部使用。由于它们在皮肤病学中是相对较新的治疗方式，许多关于其疗效和安全性的问题仍未得到解答。人们急切期待正在进行的试验的数据。在此，我们总结了正在研发的用于皮肤病的 JAK 抑制剂。
